Lesion Management to measure prostate tumours from MR scans 

Document created by adina.schoeneman Employee on Oct 24, 2016Last modified by adina.schoeneman Employee on Oct 24, 2016
Version 3Show Document
  • View in full screen mode

NIH recently published an article using the lesion management tool in Carestream Vue PACS to measure prostate tumors from MR SCANs.

 

PURPOSE:
The purpose was to evaluate a commercially available generic semi-automated tumor segmentation program using high b-value diffusion weighted magnetic resonance imaging (MRI) to estimate the total tumor burden in prostate cancer patients with whole mount histopathology as the reference standard.

 

CONCLUSION:
Carestream Lesion Management semi-automatic segmentation of prostate cancer lesions based on high b-value (b-2000) diffusion weighted MRI is a promising method to estimate tumor volume on whole mount histology. This may be useful in guiding biopsies and for more precisely defining the prostate tumor volume for brachytherapy, boost, or focal radiation therapy.

 

You can read the full publication online here

 

 

1 person found this helpful

Attachments

    Outcomes